Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Janssen Streamlines Infectious Disease and Vaccine Divisions

Janssen Streamlines Infectious Disease and Vaccine Divisions

21st July 2023

Johnson & Johnson’s revamp of its infectious disease and vaccine divisions began to take shape at the start of 2023 following a notable dip in annual earnings. They have subsequently discontinued all hepatitis related products and initiatives, as well as several treatments for HIV and the flu.

The only medications left in these portfolios are licenced for ebola, cholera, HIV, and Covid.

For now, they have decided to retain an asset for treating Dengue viral infections and are currently running trials to see how effective it is.

Johnson & Johnson described the pipeline cuts as a comprehensive “prioritization of its research and development (R&D) investment.”

They continued to explain that they will “leverage our expertise to take on entrenched threats, such as tuberculosis and leprosy, and expanding threats, like dengue, including our pan-serotype dengue antiviral, JNJ-1802.”

The most recent pipeline changes follow J&J’s decision to discontinue its respiratory syncytial virus (RSV) vaccine at the end of Q1.

Even though the Covid vaccination remains a part of their portfolio, officials informed workers at the end of January that development was slowing down on that too.

J&J’s Pharmaceutical division, Janssen, recently declared that James Merson, their lead of infectious diseases, would be leaving.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.